The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces differentiation of human breast cancer cells.

被引：0
|
作者：
Munster, PN
Rosen, N
Rifkind, R
Marks, P
Richon, V
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356
引用
收藏
页码：3725S / 3725S
页数：1
相关论文
共 50 条
  • [1] The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Induces Differentiation of Intestinal Cells
    Roostaee, Alireza
    Benoit, Yannick D.
    Guezguez, Amel
    Simoneau, Aline
    Beaulieu, Jean-Francois
    GASTROENTEROLOGY, 2014, 146 (05) : S785 - S785
  • [2] The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells
    Munster, PN
    Troso-Sandoval, T
    Rosen, N
    Rifkind, R
    Marks, PA
    Richon, VM
    CANCER RESEARCH, 2001, 61 (23) : 8492 - 8497
  • [3] Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells
    Kumagai, Takashi
    Wakimoto, Naoki
    Yin, Dong
    Gery, Sigal
    Kawamata, Norihiko
    Takai, Noriyuki
    Komatsu, Naoki
    Chumakov, Alexy
    Imai, Yasufumi
    Koeffler, H. Phillip
    INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (03) : 656 - 665
  • [4] Molecular mechanisms of underlying synergistic effect of combinations of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) with docetaxel and trastuzumab against human breast cancer cells.
    Bhalla, KN
    Bali, P
    Pranpat, M
    Fiskus, W
    Guo, F
    Sigua, C
    Swaby, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 18S - 18S
  • [5] The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma
    Ghayad, Sandra E.
    Rammal, Ghina
    Sarkis, Omar
    Basma, Hussein
    Ghamloush, Farah
    Fahs, Assil
    Karam, Mia
    Harajli, Mohamad
    Rabeh, Wissam
    Mouawad, Joe E.
    Zalzali, Hassan
    Saab, Raya
    CANCER BIOLOGY & THERAPY, 2019, 20 (03) : 272 - 283
  • [6] The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) radiosensitizes osteosarcoma cells in vitro and in vivo
    Schlaich, F.
    Blattmann, C.
    Thiemann, M.
    Kulozik, A. E.
    Debus, J.
    Oertel, S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 119 - 120
  • [7] The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in human retinoblastoma cell lines
    Poulaki, V
    Joussen, A
    Iliaki, E
    Mitsiades, CS
    Fanourakis, G
    Mitsiades, N
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U255 - U255
  • [8] The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces actin filament polymerization in HL-60 cells undergoing differentiation.
    Yao, Y
    Zhou, Q
    Ericson, SG
    BLOOD, 2003, 102 (11) : 206B - 206B
  • [9] Inhibition of oral carcinogenesis in rats by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)
    McCormick, David L.
    Horn, Thomas L.
    Johnson, William D.
    Lubet, Ronald A.
    Steele, Vernon E.
    CANCER RESEARCH, 2011, 71
  • [10] In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer
    Cooper, Amy L.
    Greenberg, Victoria L.
    Lancaster, Pamela S.
    van Nagell, John R., Jr.
    Zimmer, Stephen G.
    Modesitt, Susan C.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : 596 - 601
12345